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Background: Previous studies of blood pressure visit-to-visit variability (VVV) were of rather short duration and rarely included placebo. We 
investigated VVV of systolic blood pressure (SBP) in the active and placebo groups of Systolic Hypertension in the Elderly Program (SHEP). 
methods: SHEP was a placebo-controlled trial with a randomized phase up to 6 years in older patients with isolated systolic hypertension. We 
ascertained death from the National Death Index. Variability of intraday mean to SBP trend (rSSR), variance of absolute values of second differences 
of successive daily SBP (VABS2) and Variance Independent of Mean (VIM) obtained from the first 2 years (randomization to the end of 24 months) 
were used to predict outcomes. Outcomes were: the first occurrence of stroke, myocardial infarction or heart failure after the first 2 years (4 years 
follow up) and cardiovascular death after 2 years up to 17 years (15 years follow up). Cox proportional hazards models adjusting for gender, age, 
serum creatinine, diabetes, body mass index, smoking, left ventricular failure and high-density lipoprotein cholesterol were used. 
results: The relationship of SBP VVV to outcomes was stronger in the active treatment group than in the placebo group. VIM was a weaker predictor 
of outcomes. 
conclusion: SBP VVV predicted morbid and fatal outcomes. This was observed primarily in the active treatment group implying that missing doses 
of medications may be an additional explanation for the relationship of VVV with outcomes.
Treatment groups Outcome Type of analysis rSSR VABS2 VIMHR (95% CI) HR (95% CI) HR (95% CI)
Active treatment
Combined Event
Unadjusted
1.0090*
(1.0020, 1.0160)
1.0000
(0.9998, 1.0010)
1.0760
(0.8874, 1.3050)
Adjusted
1.0070
(0.9994, 1.0153)
1.0001
(0.9995, 1.0007)
1.0769
(0.8764, 1.3230)
17-Year CV death
Unadjusted
1.0130***
(1.0080, 1.0170)
1.0010***
(1.0010, 1.0010)
1.2830 ***
(1.1360, 1.4480)
Adjusted
1.0049*
(1.0001, 1.0100)
1.0005**
(1.0002, 1.0010)
1.0779
(0.9450, 1.2290)
Placebo
Combined Event
Unadjusted
1.0070*
(1.0010, 1.0130)
1.0000
(1.0000, 1.0010)
1.1110
(0.9402, 1.3130)
Adjusted
1.0057
(0.9993, 1.0122)
1.0002
(0.9997, 1.0007)
1.1083
(0.9299, 1.3090)
17-Year CV death
Unadjusted
1.0040*
(1.0000, 1.0080)
1.0000
(0.9998, 1.0010)
1.1240*
(1.0120, 1.2480)
Adjusted
1.0001
(0.9957, 1.0046)
1.0000
(0.9996, 1.0000)
1.0080
(0.8982, 1.1310)
*p-value < 0.05, **p-value < 0.001 , ***p-value < 0.0001
